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Abstract. It is widely accepted that today’s practice of polypharmacy inevitably increases the incidence of
drug–drug interactions (DDIs). Serious DDI is a major liability for any new chemical entity (NCE)
entering the pharmaceutical market. As such, pharmaceutical companies employ various strategies to
avoid problematic compounds for clinical development. A key cause for DDIs is the inhibition of
cytochrome P450 enzymes (CYPs) that are responsible for metabolic clearance of many drugs. Screening
for inhibition potency of CYPs by NCEs has therefore become a routine practice during the drug
discovery stage. However, in order to make proper use of DDI data, an understanding of the strengths
and weaknesses of the various experimental systems in current use is required. An illustrated review of
experimental practices is presented with discussion of likely future developments. The combination of
high quality in vitro data generation and the application of in vivo CYP inhibition modelling approaches
should allow more informed decisions to be made in the search for drug molecules with acceptable DDI
characteristics.
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INTRODUCTION
Cytochrome P450 enzymes (CYPs) are found in practi-
cally all living organisms and have been retained and adapted
through evolution due to their unusual ability to oxidise
carbon–hydrogen bonds in a regio- and stereo-selective
manner. In addition to performing essential biosynthetic and
metabolic functions (e.g. structural and signalling molecule
biosynthesis, bacterial activation of hydrocarbons for use as
carbon sources) animal P450 enzymes also act as important
systems for the detoxiﬁcation of phytochemicals and other
xenobiotics. The human CYP enzymes which have evolved to
dispose of a wide variety of dietary and environmental toxins
now perform the same function in removal of lipophilic small
molecule (molecular weight <1,200 Da) drug substances from
the body.
In the development of a new drug substance, a balance
must be reached between the amount of drug which is to be
administered and the rate of drug clearance in order to
achieve the desired therapeutic plasma or tissue concentra-
tion for the required amount of time. As the clearance of
most small molecule drug substances is dependent upon CYP
enzymes, their inhibition can lead to overexposure and
toxicity. Considerable effort is therefore expended in the
pharmaceutical industry on optimisation of molecules to
avoid pharmacokinetic drug–drug interactions (DDIs) due
to CYP inhibition. Although the number of individual CYPs
and the number of allelic forms of these enzymes which have
been identiﬁed is still increasing, the most important enzymes
involved in drug metabolism have been known for some time
and are described in standard texts (1). To date, it is still most
important to identify potent inhibitors of CYP3A4 followed
by CYP2C9, CYP2D6, CYP2C19 and CYP1A2. Additionally
CYP2C8 and CYP2B6 have been added to the list of enzymes
which are recommended for testing in regulatory studies (2).
The aim of this review is to give a basic description of
current experimental practices and data extrapolation, with
their advantages and disadvantages. There are already many
excellent discussions of CYP inhibition and, particularly in
the last year, of time-dependent CYP inhibition. Therefore,
where the same ground is covered in this review, it is from a
more experimental rather than a theoretical point of view.
IN VITRO EVALUATION OF CYP INHIBITION
In Vitro Methodologies
A short description of the methods used to measure
enzyme activity, and hence enzyme inhibition, is required if
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fowler@roche.com)different experimental systems and screening strategies are to
be discussed. As the CYP metabolism reaction cycle consists
of substrate binding, enzyme reduction (NADPH oxidation),
oxygen reduction, substrate oxidation and product release,
there are a number of steps which could be monitored to give
an indication of enzyme inhibition by a test substance. In
practice however, CYP inhibition measurement is almost
always performed by analysing inhibition of substrate metab-
olism. The different technologies available for measurement
of metabolite generation can be categorised as high, medium
and low throughput methods (Table I).
In the most frequently applied high throughput method,
CYP activity results in oxidation of a pro-ﬂuorescent
molecule which then breaks down to give a ﬂuorescent
product (usually a hydroxycoumarin, ﬂuorescein or resoruﬁn
analogue). These products can then be detected directly using
a ﬂuorescence plate reader. This method has the advantage
that it is a fast and cost-effective way to perform thousands of
IC50 determinations per year (3,4). Measurements may be
subject to interference from test inhibitors which either
ﬂuoresce or cause ﬂuorescence quenching. However, al-
though these effects are observed, in practice their frequency
is usually acceptably low. For example, ﬂuorescence and
ﬂuorescence quenching resulted in assay failure rates of
between 0.1 and 0.8% in over 5,000 compounds tested in
2007, accounting for between 12 and 49% of total failures
(Table II).
An analogous high throughput method involves the use
of pro-luminescent substrates. Here, CYP activity results in
the generation of a luciferin analogue which can be made to
luminesce by addition of a development reagent (5). The
advantage of luminescence technology is the greatly im-
proved signal to noise ratio which can be achieved, although
there are the drawbacks of needing an extra “development”
step in the assay process and not being able to read the signal
generation in real time. A requirement of both of these high
throughput technologies is that recombinantly expressed
single enzymes are used, due to insufﬁcient enzyme selectivity
of most probe substrates to allow their use with human liver
microsomes (HLM), which contain a mixture of many
different enzymes.
Technologies which make use of CYP-selective sub-
strates (marketed or formerly marketed drug substances or
well characterised biomolecules such as steroids) and can be
implemented on a medium throughput basis are the release of
radioactivity from a substrate molecule and liquid chroma-
tography–tamdem mass spectrometry (LC-MS)/MS analysis
of metabolite generation from unlabelled drug substance
molecules. As studies conducted using HLMs and existing
drugs as substrates are felt to be closest to the in vivo DDI
situation, they are the preferred systems for CYP inhibition
screening and the accepted methods for regulatory in vitro
DDI studies.
The radiometric methods rely upon release of either
tritiated water (following hydroxylation of a labelled C–
3H
moiety and proton exchange with buffer water (6,7)) or
14C-
formaldehyde (following oxidative O- or N-demethylation of
a −
14CH3 labelled drug molecule (8)). Unfortunately, both of
Table I. Methods of CYP Inhibition Measurement
Method Comment Pro Con
Fluorescence
(high throughput)
Pro-ﬂuorescent substrate
metabolised to give
ﬂuorescent product
Measures actual enzyme activity.
Fast. Sensitive. Cost-effective.
Easy miniaturisation allows
high throughput. Kinetic
mode measurements possible
Recombinant enzymes needed as probes
not CYP selective enough for HLM.
Correlation to HLM assay needed.
Interference from ﬂuorescent or
ﬂuorescence quencher molecules
Luminescence
(high throughput)
Pro-luminescent substrate
metabolised to luminescent
product
Very sensitive Work-up reagent required. High SDS
content of quench reagent not suited
to all automated sample pipettors.
Recombinant enzymes needed for
most enzyme measurements as truly
selective reagents are not yet
developed for all important drug
metabolising CYPs
Radiometric
(medium throughput)
Release of radiolabel on
metabolism of substrate
(typically as
14C-formaldehyde
or as
3H-water)
Fast and accurate. Can use HLM Solid phase separation and liquid or
solid scintillation counting required.
Large amount of radiolabelled
substances used. Disposal of
radioactive wastes
Radiometric
(low throughput)
Metabolism of labelled substrate
analysed by HPLC-radioﬂow
or HPLC based fraction
collection/scintillation
counting technologies
Almost free choice of substrate
molecules
Analysis slow
LC-MS/MS,
(medium throughput)
Industry standard method for
all high quality/moderate-
high throughput DDI
assessments
Free choice of substrates allows
HLM or recombinant CYP use.
LC-MS/MS analysis technology
sensitive and speciﬁc
Signiﬁcant investment in analytical
equipment required
SDS sodium dodecyl sulfate, HPLC high-performance liquid chromatography
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separation of the labelled metabolite from labelled parent
material. They also involve extensive use of radiolabelled
materials, which is undesirable from both cost and radioactive
substance disposal perspectives.
With the development of more sensitive LC-MS/MS
machines and the almost ubiquitous use of MS within drug
metabolism research centres, LC-MS/MS has become the
standard measurement technology for in vitro DDI experi-
ments. The routine analysis of only a few metabolite
substances has facilitated the development of high quality,
short run-time, LC-MS/MS analysis methods (9). The possi-
bility to pool samples for analysis or to cassette substrates in
incubations have further enhanced the throughput of LC-MS/
MS based CYP inhibition assays for early discovery work
(10,11). These advances have allowed fast, accurate measure-
ments to be brought to DDI studies in at least a medium
throughput, if not yet a high throughput manner.
The 2006 draft guidance from the American Food and
Drug Administration about the conduct of DDI investigationsis
highly prescriptive with a large amount of proposed experimen-
tal detail included and helpful (although not exhaustive) tables
of substrates and inhibitors in common usage (2). In addition,
many authors have described method conditions for the
assessment of DDI in vitro, the most thorough of these coming
from the lab of Walsky and Obach (9,12,13).
Choice of Substrate Concentrations
Characterization of CYP inhibition is typically conducted
at substrate concentrations where CYP catalysis follows
Michaelis–Menten kinetics to avoid complications in data
interpretation. Here, the relationship between the rate of
catalysis and substrate concentration is consistent with
substrate association with a single enzyme binding site and
follows hyperbolic substrate-saturation kinetics. A good
example of this is the CYP2C19-selective 4′-hydroxylation
of S-mephenytoin (Fig. 1a), where reaction rate data ﬁt well
to the formula v=vmax*[S]/(KM+[S]) over the entire concen-
tration range tested. In contrast midazolam, which exhibits
CYP3A4/CYP3A5 selective 1′-hydroxylation by HLMs and is
frequently used as a CYP3A substrate for inhibition studies,
clearly shows substrate inhibition kinetics (Fig. 1b). To allow
straightforward data extrapolation, low (up to 5 μM, Michaelis–
Menten kinetics still followed) concentrations of midazolam are
therefore used experimentally.
Fig. 1. ExamplesofhumanlivermicrosomalkineticsforS-mephenytoin
4′-hydroxylase and midazolam 1′-hydroxylase activities. a Human liver
microsomal S-mephenytoin 4′-hydroxylation rate data are explained
well by the Michaelis–Menten kinetic model over the entire concen-
tration range tested. b In contrast, midazolam 1′-hydroxylase activity
data could only be modelled using the Michaelis–Menten kinetic
equation at midazolam concentrations up to ∼5 μM. Higher concen-
tration data conformed to substrate inhibition kinetics. For midazolam,
only concentrations of up to ∼5 μM can therefore be used in IC50 and
Ki determinations if data treatments with assumptions based upon
Michaelis–Menten kinetics are to be used. [Experimental conditions: S-
Mephenytoin: 1–200 μM S-mephenytoin incubated with 0.5 mg/ml
pooled HLMs (BD-Gentest) and 1 mM NADPH for 15 min at 37°C in
the absence of solvents. Midazolam: 1–60 μM midazolam incubated
with 0.15 mg/mL pooled HLMs, at 37°C with 1 mM NADPH for 5 min
(DMSO content: 0.25% v/v)]
Table II. Frequency of IC50 Values Exceeding Aqueous Solubility and Assay Failure Rates for Three Fluorescence-Based CYP Inhibition
Screens
IC50/Solubility
All IC50 values IC50<50 μMI C 50>50 μM
n
a
Percentage Assay
Failure Rate (n)
Failure Rate
Due to Fluorescence
or Fluorescence
Quenching (%) <1 1–33 –10 >10 <1 1–33 –10 >10 <1 1–33 –10 >10
CYP2C9 (MFC) 79.8 12.1 5.4 2.7 49.7 10.9 4.9 0.5 30.1 1.2 0.5 2.2 4,688 1.64 (5,508) 0.80
CYP2D6 (AMMC) 71.4 11.5 10.7 6.4 49.6 9.8 9.9 2.3 21.8 1.7 0.8 4.1 4,723 0.94 (5,402) 0.11
CYP3A4 (DBF) 68.6 12 9.6 9.8 25.6 8.6 7.9 2.6 43 3.4 1.7 7.2 4,747 0.48 (5,433) 0.09
aNumber of molecules where both CYP inhibition and high throughput solubility data were available.
412 Fowler and ZhangNonMichaelis–Mentenkineticshasbeendemonstratedfor
many CYP mediated reactions. This is generally rationalised in
terms of the ability of more than one substrate molecule to bind
to the enzyme simultaneously, giving rise to both autoactivation
and auto-inhibition effects (dependent upon the enzyme,
substrateandsubstrateconcentrations).Manyacademicreports
of such atypical kinetics can be found in the literature (14–17)
with complex modelling approaches proposed, as well as more
straightforward reviews of the topic (18,19).
From a practical point of view, when developing an
inhibition assay a combination of enzyme concentration,
substrate, substrate concentration and incubation time must
be chosen for which:
& Substrate metabolism rate does not change signiﬁcantly
during the incubation (ideally less than 10% substrate
depletion).
& Substrate metabolism is sensitive to the presence of
inhibitory compounds (substrate not at saturating
concentrations;ideally at, or below, KM concentration).
& Sufﬁcient metabolite is generated to be able to quantify
enzyme activity even when the enzyme is 95% inhibited.
& Final solvent content is low enough not to cause
dramatic enzyme inhibition (20,21).
& The probability of in vitro activation effects (Fig. 2f) is
minimised (choice of substrate, use of S50 rather than
lower concentrations for substrates displaying auto-
activation kinetics).
CYP Inhibition Measurement: IC50 Determination
The basic assay to assess the interaction potential of a
new chemical entity is the IC50 determination. Here, the
inhibitory effect of a test compound is measured and the
concentration expected to cause 50% enzyme inhibition
reported. The standard method, in which a serial dilution of
the test inhibitor in DMSO (or other organic solvent) is
performed, maximises the chance that the inhibitor is in
solution before being added to the incubation mixture and
allows each concentration tested to be as independent of the
other measurements as possible. Nevertheless, the highly
lipophilic nature of many early lead compounds results in
frequent solubility problems. It is therefore important to
consider the effect of test inhibitor precipitation after addition
to the incubation mixture. Here, four different scenarios can
be envisaged: (1) The IC50 is signiﬁcantly lower than the test
inhibitor solubility, resulting in normal inhibition behaviour
(Fig. 2a). (2) The IC50 is somewhat lower than, or equal to,
the solubility limit: In this case the IC50 can be determined
but data points from concentrations above the solubility limit
must be excluded (Fig. 2b). An IC50 curve should still be
ﬁtted to the data using the 0 and 100% activity values
determined for the experiment as a whole and not ﬁtted to
the maximum effect generated by the inhibitor at its
saturation concentration in the incubation media (as shown
in Fig. 2c). (3) The IC50 is higher than the solubility limit.
How clear this will be depends upon the quality of the
experimental data, the spacing of the different inhibitor
concentrations and the number of data points above the
solubility limit (Fig. 2d). “IC50 > highest concentration where
effect was measured with conﬁdence” or “IC50 not deter-
mined” should be reported accordingly. (4) Where the IC50 is
signiﬁcantly higher than the solubility limit, a saturated effect
proﬁle may be generated (Fig. 2e). With such data, one
should not allow an IC50 value of >50 μM (or highest test
concentration) to be automatically reported. A clearer picture
might be obtained by repeating the experiment using lower
inhibitor concentrations.
Given sufﬁcient time and resource, it would be possible
to measure the test inhibitor solution concentration in each
incubate, or to use nephelometric methods to try to detect
precipitation. In practice however, this resource is not
normally applied. Flagging of potentially insoluble com-
pounds whose data should be treated with caution can be
quickly performed if high throughput solubility (or in silico
solubility prediction) data is available. In an analysis of over
5,000 compounds tested for CYP inhibition potency in 2007
using ﬂuorescence-based screening methods, it was observed
that the IC50 value reported exceeded the aqueous solubility
limit in 20–30% of all determinations where solubility data
was available (Table II). Using a threshold of IC50/aqueous
solubility >10 to ﬂag the most potentially erroneous data
resulted in identiﬁcation of between 3% and 10% of
compounds tested, dependent upon the enzyme assay. Of
these, it was most important to consider the 2–7% of cases
whose IC50 values were reported as >50 μM (highest test
concentration) as it was more likely that these substances had
solubility problems which were not detected. Such substances
present a risk of generating misleading structure–activity
relationships within a chemical series and perhaps encourag-
ing chemical effort to be directed toward reducing solubility
as a way to avoid in vitro enzyme inhibition. A more reﬁned
approach to the ﬂagging process could be employed by
measuring or predicting the degree of microsomal protein
binding and hence comparing the unbound inhibitor concen-
tration with the substance solubility. Formulae for estimation
of microsomal protein binding have been proposed by Austin
et al (22) and Hallifax and Houston (23).
An accurate and useful screen can be set up by
determining the percentage inhibition caused by a test
substance at one (or more) deﬁned concentrations (e.g.
3 μM) (24,25). However, the requirement to re-test com-
pounds of interest means that when developing a screening
strategy including compound supply logistics and short turn-
around times it is often more efﬁcient simply to perform an
IC50 determination for each test substance. In addition,
testing at a single inhibitor concentration does not allow
deviation from the expected concentration-dependent inhibi-
tion effect behaviour to be observed, leaving more scope for
the reporting of false negative results due to substance
insolubility. The IC50 determination experiment makes no
distinction as to whether a compound causes enzyme
inactivation or reversible inhibition and cannot distinguish
between kinetic mechanisms of reversible inhibition. Further
studies therefore need to be performed to characterise the
mechanism of inhibition for compounds of interest.
CYP Inhibition Measurement: Ki Determination
and Mechanism of Reversible Inhibition
For inhibitors of substrates which follow Michaelis–
Menten kinetics tested at the KM concentration of substrate,
413 In Vitro CYP Inhibition Measurement: Current Status and DDI PredictionFig. 2. IC50 data analysis and troubleshooting. Plots of percent control activity against inhibitor
concentration (real compound data from HLM midazolam 1′-hydroxylase activity inhibition experiments
analysed by LC-MS/MS). a Desired effect proﬁle for IC50 determination; b Solubility problems prevent use
of highest concentration datapoints but IC50 value can still be estimated (full range of enzyme activity used
in IC50 determination); c Data as in b, but data processed using measured activity asymptotes for this
compound, resulting in an under-estimate of the IC50 value; d Data difﬁcult to interpret due to solubility
limitation, “IC50 >3 μM” or “IC50 not determined” could be reported; e Solubility limit likely to be below
lowest inhibitor concentration tested in the experiment. Care should be taken not to automatically assign
an IC50 value of >50 μM; f In vitro activation indicates inhibitor binding to enzyme at concentrations of 1 –
10 μM exists but IC50 value could not be determined. Inhibition should be assessed using alternative
substrates
414 Fowler and ZhangKi values fall between IC50/2 (competitive inhibitors) and IC50
(non-competitive inhibitors). IC50 values therefore give sufﬁ-
cient information to have a good indication of the inhibition
potency of a potential new drug substance and allow compar-
ison with other candidate molecules. However, for a thorough
assessment of DDI effects in vivo,K i values are required. The
Ki is dependent upon inhibitor and substrate, but independent
of substrate concentration used. Depending on the mode of
interaction between CYP enzymes and inhibitors, reversible
CYP inhibition may be further described as competitive, non-
competitive, uncompetitive and mixed.
Ki experiments typically use a matrix of substrate and
inhibitor concentrations spanning a range of at least ∼0.5–5x
expected Ki (inhibitor) and KM (substrate) concentrations.
Data are usually presented in the form of Dixon plots of 1/
reaction rate vs inhibitor concentration. Ki determinations are
limited in a practical sense by:
& Inhibitor solubility.
& Limit of detection of inhibited enzyme activity.
& Acceptable turnover limit for substrate to avoid devi-
ation from initial rate conditions (substrate depletion).
& Limit of substrate concentrations which can be tested
and remain within the range of Michaelis–Menten-
like kinetics. (Due to allosteric activation, solubility
or substrate inhibition effects.)
These restrictions are shown graphically in Fig. 3.A si n
all graphical solutions generated using 1/rate data, care must
be taken to avoid undue inﬂuence from the lowest turnover
rate data (largest 1/rate values), which typically have the
greatest percent variability and are the most subject to
allosteric kinetic effects.
Where accurate determinations of enzyme activity have
been performed and where Michaelis–Menten kinetics of
substrate metabolism is known, accurate estimates of Ki can
be made and a mechanism of inhibition assigned. However,
although standard texts (1,26) show clear graphs depicting
how the different interaction mechanisms can be assigned,
using real data it is often not so easy. In these cases, a
straightforward approach to the problem is to make use of a
direct plot of reaction rate vs substrate concentration (Fig. 4a)
and to assess how the apparent KM and vmax values change with
increasing inhibitor concentrations, as detailed in Table III.
Once a model has been selected, simultaneous non-linear
regression using all the data points can be performed, plots
generated of the ﬁtted solution (Fig. 4b) and the solution
inspected for the inﬂuence of outlier points and consistency of
the Ki and IC50 values (if IC50 previously determined). Once
Ki and mechanism of inhibition have been assigned, extrap-
olations to expected clinical DDI effect can be attempted, as
discussed later.
CYP Inhibition Measurement: Determination
of Time-Dependent Inhibition
Time-dependent inhibition (TDI) is a term which covers
any phenomenon resulting in reduction of enzyme activity
with incubation time. A detailed description of the kinetic
characteristics of this type of inhibition can be found in the
text by Silverman (27). Although TDI can arise for a number
of reasons (including the formation of potent yet reversible-
binding metabolites (28–30)), the most important molecular
mechanisms are:
(1) Generation of reactive electrophiles (typically from
furan, thiophene, acetylene and alkene groups)
which react with the P450 to form covalent adducts
of the heme or apoprotein, inactivating the enzyme.
Fig. 3. Experimental restrictions in Ki determinations: Substrate depletion—ideally <10% metabolism of
substrate (and inhibitor) during incubation so little deviation from initial rate conditions. Product detection—
limit of metabolite quantitation (analysis sensitivity). Solubility—both substrate and inhibitor must be in solution
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“mechanism based inhibition”. Here, the enzyme
activity cannot be recovered by dialysis of the
incubate and a 1:1 stoichiometry of enzyme inactiva-
tion and inhibitor-enzyme adduct generation is
expected.
(2) The formation of tight-binding complexes between
the P450 heme and metabolites of particular chem-
istries, whose off-rate is so low that the enzyme
activity is essentially removed from the in vitro incuba-
tion system. Alkylamine and benzodioxazole moieties
are the principal functional groups involved here. This
is often referred to as “quasi-irreversible” inhibition as
CYP activity can be recovered by dialysis (28).
Chemical mechanisms of TDI have been very well
reviewed by Kulgutkar, Obach and Maurer (31) and previ-
ously by Guengerich (32). Inactivation of CYP enzymes by a
compound in vivo can lead to large and long-lasting DDI
effects as the metabolic capability can only be restored by
new enzyme synthesis, a process taking place over a timescale
of days. Detection and amelioration of TDI activity is
therefore an important aspect in DDI optimisation for
compounds under development. The different experimental
methods used for TDI detection, along with their advantages
and limitations, are described below.
TDI Methods: IC50 Shift on Preincubation
Assessing whether there is any change in the IC50 value
for a test inhibitor with or without inhibitor preincubation
with the enzyme system makes a straightforward and useful
method for the initial detection of TDI effects. Here, the test
inhibitor is incubated with HLMs (or recombinant enzyme)
and NADPH (or NADPH regenerating system) for 20–
30 min. After this time the substrate is added and the mixture
incubated for a further time (normally 3–10 min). Identical
incubations are run in parallel lacking the preincubation step
(or with preincubation lacking NADPH). 100% and 0%
activity control incubations are run for each part of the
experiment. Plotting percent control enzyme activity against
log(inhibitor concentration) gives sigmoidal inhibition curves
for each set of data (Fig. 5). When the inhibition curve is
shifted to lower IC50 value by the preincubation treatment,
this is an indication of TDI.
The advantages of this method are that it is:
& Straightforward to perform and the data analysis
proceeds using the same processing methods as are
already established in most labs.
& The data output is fairly clear and little additional
knowledge is required to appreciate a positive result
in the experiment.
& Many inhibitor concentrations are tested in a single
experiment, ensuring that testing in a sensitive region
of the concentration-effect curve should occur.
Table III. Kinetic Characteristics of Reversible Inhibition Models
With increasing inhibitor concentration
Inhibition model Rate equation Apparent KM Apparent vmax
Increases Unchanged Competitive v ¼ vmax   S ½  = KM   1þ I ½  =Ki ðÞ ðÞ þ S ½  fg
Increases (Ki′>Ki)
Decreases (Ki′<Ki)
Decreases Mixed competitive/non-competitive v ¼ vmax  S ½ 

KM   1þ I ½  =Ki ðÞ ðÞ þ S ½   1þ I ½ 

K0
i
  
Unchanged Decreases Non-competitive v ¼ vmax  S ½  = KM   1þ I ½  =Ki ðÞ ðÞ þ S ½   1þ I ½  =Ki ðÞ ðÞ fg
Decreases Decreases Uncompetitive v ¼ vmax  S ½  = KMþ S ½   1þ I ½  =Ki ðÞ ðÞ fg
Fig. 4. Ki Determination using all datapoint non-linear regression
method. a Direct plot of human liver microsomal S-mephenytoin 4′-
hydroxylase activity against substrate concentration for each inhibitor
concentration tested. Increasing inhibitor concentration resulted in
reduced apparent vmax and increased apparent KM, hence a mixed
competitive – non-competitive inhibition model selected and used as
shown in Fig. 4b. b Dixon plot of 1/(human liver microsomal S-
mephenytoin 4′-hydroxylase activity) against inhibitor concentration
for each substrate concentration tested, with mixed competitive–non-
competitive inhibition model ﬁtted by non-linear regression using all
data simultaneously (Origin 7.03, OriginLab Corp). Ki and Ki′
estimates of 12±2 and 24±2μM were generated
416 Fowler and ZhangDisadvantages are that:
& Enzyme inactivation continues during the incubation
phase of the experiment.
& Generation of metabolites which are more inhibitory
than the parent substance will look like TDI.
& The reverse effect (shift of curve to higher IC50
value) can occur where the test inhibitor is signiﬁ-
cantly depleted without enzyme inactivation (Fig. 5b
and c). This can be seen for highly metabolically
unstable compounds and substances tested at very
low concentrations. A balance between test substance
metabolism (to non-inhibitory products) and enzyme
inactivation may look like no inhibition effect.
& Assay variability must be small enough to allow a
detectable IC50 shift to be generated by low potency
TDI substances.
An enhanced version of this assay in which both a
preincubation and a dilution are performed gives the capacity
to leverage the enzyme inactivation effect to produce more
dramatic IC50 shifts, to reduce the potential problem of
inhibitory metabolite generation (by dilution away from
enzyme) and potentially to enhance the method sensitivity
(33) (Fig. 5). The utility of this method can be seen for
saquinavir (Fig. 5c), where the dilution effect allows enzyme
inactivation to be detected despite substantial inhibitor
metabolism. However, some care must be taken not to
Fig. 5. Examples of IC50 shift assay for detecting TDI: a Inhibition of human liver microsomal midazolam 1′-hydroxylase activity by 17α-
ethynylestradiol. Rightmost curve (squares and solid line,I C 50=49 μM): determination with no preincubation (0.2 mg/ml HLM, 5 min
incubation time). Centre curve (circles and dashed line,I C 50=8.3 μM): determination with 30 min preincubation in the absence of substrate
(0.25 mg/ml HLM in preincubation, 0.2 mg/ml HLM in incubation, 5 min incubation time). Leftmost curve (triangles and dotted line,I C 50=
0.89 μM): determination with 30 min preincubation and 10-fold dilution before incubation (0.2 mg/ml HLM in preincubation, 0.02 mg/ml HLM
in incubation, 5 min incubation time). b Experiment examining α-naphthoﬂavone inhibition of human liver microsomal ethoxyresoruﬁnO -
deethylase activity (principally CYP1A2 mediated). Squares and solid line: no preincubation, circles and dashed line: with 30 min preincubation.
Preincubation resulted in metabolism of α-naphthoﬂavone but not in enzyme inactivation, so curve shifted to higher IC50 value. c Human liver
microsomal midazolam 1′-hydroxylase activity inhibition by saquinavir. Squares and solid line: no preincubation; circles and dashed line: 30 min
preincubation, metabolism of saquinavir in lower concentration incubations outweighs enzyme inactivation so curve shifted to higher IC50
value and sigmoidicity increased; triangles and dotted line: 30 min preincubation and 10-fold dilution allows enzyme inactivation effect to
become apparent. d: Human liver microsomal midazolam 1′-hydroxylase activity inhibition by ketoconazole. Squares and solid line:n o
preincubation; circles and dashed line: 30 min preincubation—no change in apparent inhibition potency as enzyme not inactivated; triangles and
dotted line: 30 min preincubation and 10-fold dilution—curve shift to lower IC50 value due to enzyme/protein dilution
417 In Vitro CYP Inhibition Measurement: Current Status and DDI Predictionintroduce artefacts into an otherwise straightforward experi-
mental protocol. For instance, when ketoconazole is tested in
this way an IC50 shift due to changes in enzyme and protein
concentration can be seen (Fig. 5d). If HLM dilution is made
into protein solution, this effect is substantially reduced.
TDI Methods: Following Reaction Progress Curves (Kinetic
Measurement Protocol)
A seldom applied method (recently been exempliﬁed in
a study by Fairman et al (34)) observes the change in
metabolism rates with incubation time in the presence of
different inhibitor concentrations. It can either be performed
using a large number of individual endpoint measurements or
by using a ﬂuorescence plate reader running in kinetic mode.
The progress curve method has the advantage of allowing
TDI to be detected in the same experiment as the IC50
determination. A large number of datapoints need to be
generated and simultaneous ﬁtting of all the data is then used
to estimate Ki,K I and kinact values. The method has the
disadvantages that:
& Either pro-ﬂuorescent substrates must be used in
order to allow kinetic measurements in real time or a
large number of samples must be measured using LC-
MS/MS, luminescence, radioactivity or other end-
point measurement technologies.
& Very high signal measurement sensitivity and accura-
cy are required to allow changes in the rate of
metabolite generation throughout the incubation to
be observed, especially where enzyme activity is low
(due to high levels of competitive inhibition).
& Substrate competes with inhibitor to bind to the P450,
partially shielding the enzyme from inactivation.
& Generation of inhibitor metabolites more potent than
the test inhibitor will give the appearance of TDI.
TDI Methods: Preincubation–Dilution–Incubation Method
This is the classical method of determining TDI effects
(35). After different preincubation times, aliquots of the
enzyme-inhibitor mix are diluted into substrate solution and
the remaining enzyme activity determined. The method has
the distinct advantages that the inhibitor (and its metabolites)
can be diluted away from the enzyme at the end of the
preincubation time, minimising further enzyme inhibition and
allowing enzyme inactivation to be distinguished from
inhibitory metabolite generation. Data outputs are the
inactivation rate constants (kobs(inhibitor, conc) = −slope in plot
of ln(activity) vs preincubation time) and percent time-
dependent enzyme inactivation following a given preincuba-
tion time. The assay can be deployed in both screening and
kinetic characterisation modes: In a screening mode, many
substances can be each tested at a single concentration, e.g.
10 μM, and the kobs values compared within a chemical series
or against absolute values benchmarked using known TDI
positive substances (e.g. <0.005 min
−1 within background
noise, 0.005–0.025 min
−1 moderate TDI substances,
>0.025 min
−1 highly positive TDI substances). Where a
positive result is found for a compound of interest, a kinetic
characterisation of the TDI effect should be performed, in
order to estimate the TDI effect at clinically relevant
concentrations.
In a TDI kinetic characterisation, kobs values are
determined for many inhibitor concentrations, and hence
the kinetic constants kinact (maximal rate of enzyme inactiva-
tion) and KI (concentration of inhibitor giving half-maximal
enzyme inactivation rate) estimated (Fig. 6). A hyperbolic
model kobs ¼ kinact* I ½  = KI þ I ½  ðÞ ðÞ readily allows kinact and
KI estimation, with a good ﬁt to the experimental data
achieved for most compounds. Ghanbari et al have shown
that many published studies of TDI which followed this
method were limited by insufﬁcient enzyme dilution and
over-long incubation times (36). However, with increased LC-
MS/MS method sensitivity it is possible to minimise the
Fig. 6. TDI of human liver microsomal midazolam 1′-hydroxylase
activity by bergamottin. Preincubation performed using 1 mg/ml
HLM (pooled, BD-Gentest) 1 mM NADPH and 0–50 μM berga-
mottin. Aliquots diluted 10-fold to make incubations (10 min)
containing 10 μM midazolam, 0.1 mg/ml HLM and 1 mM NADPH.
a Activity decay proﬁles for each test concentration; Inactivation rate
constants calculated from plots of ln(percent initial control activity)
against preincubation time. First two (three for lowest bergamottin
concentrations) datapoints used for initial inactivation rate estimations.
b Non-linear regression of formula kobs ¼ kinact*I ðÞ = KI þ I ðÞ using
Origin v7.03 (OriginLab Corp) gave estimates of KI=21±1 μMa n d
kinact=0.55±0.01 min
−1
418 Fowler and Zhangresidual effect of the inhibitor after the dilution step by using
a dilution factor of 20- (or even 50-) fold, with incubation
times of 3–5 min. These improvements should reduce the bias
possible in many TDI experiments where the incubation time
was comparable to the preincubation time and dilution
factors of less than 10 were sometimes used. In addition,
preincubation times need to be tuned to the inhibitor
investigated: highly effective TDI substances require short
preincubation times in order to inactivate the ﬁrst 90% of
enzyme activity which is most accurately measured, whereas
less effective TDI substances require substantial preincuba-
tion times to generate sufﬁcient enzyme inactivation for
measurement. Generic TDI determination methods must
therefore include a combination of both short and longer
preincubations times.
PROBLEMS WITH CYP INHIBITION
DATA—DIFFERENT RESULTS FROM DIFFERENT
SYSTEMS
In theory, the same IC50 value should be generated for
inhibition of the same enzyme when performed under the
same conditions (protein concentration, solvent concentra-
tion, buffer, enzyme source) if different substrates are used at
the KM concentration. However, this is often not the case in
practice. In CYP inhibition screening, this phenomenon is
principally due to two separate problems: Firstly, high
variability exists in the degree of correlation between
inhibition data generated using recombinant enzymes and
ﬂuorescent probe substrates and those generated using
HLMs and classical (often referred to as ‘drug-like’) sub-
strates. Secondly, there are differences in inhibition activities
of test compounds, dependent upon the substrate chosen for
some CYPs, especially CYP3A4. Both of these problems and
their consequences are discussed below.
Requirement for Correlation Between Assay Systems
The human liver microsomal assay is accepted as the
‘gold standard’ for in vitro DDI assessment as it is felt to be
closest to the native enzyme environment without the batch
variability, potential transporter involvement and cell pene-
tration complications associated with human hepatocytes. This
assay is therefore used to characterise development com-
pounds where data will be submitted to regulatory authorities.
In companies where additional assay systems (typically
ﬂuorescence-based) are used for early discovery stage high
throughput CYP inhibition screening, there is a need to
ensure that the data generated by the screening and regula-
tory assays correlate. Unfortunately, this is not always the case
for many project chemistries under development today, which
may call into question the utility of data generated using pro-
ﬂuorescent probe substrates, despite the technically excellent
nature of the assay (in terms of sensitivity, speed, cost-
effectiveness and reproducibility). Awareness of the reasons
for such discrepancies and individual project guidance are
therefore needed when dealing with CYP inhibition problems
during lead optimisation (Fig. 7). Effects contributing to
differences in data between assay types are discussed below.
Differences in protein, lipid and co-enzyme content. It is
normally assumed that only the inhibitor and substrate which
are free in solution are available to interact with the enzyme
system. As the recombinant enzymes often have a much
higher P450 content per milligram protein than HLMs, there
can be a signiﬁcant difference in the amount of total protein
required to run an inhibition assay. The sensitivity of IC50
values to microsomal concentration has been observed for
many compounds and particularly well characterised in the
case of montelukast, a CYP2C8 selective inhibitor (37). Here,
a 10-fold increase in IC50 value was observed when the human
Fig. 7. Comparison of IC50 values generated using recombinant CYP/pro-ﬂuorescent substrate and HLM/‘drug-like’ substrate. Comparison of
IC50 data generated using recombinant CYP2C9 (50 pmol/ml E. coli expressed CYP2C9, 15 min incubation time, MFC as substrate) and with
those generated using HLMs (0.2 mg/ml pooled HLMs (BD-Gentest), 5 min incubation time, 5 μM diclofenac as substrate) for three chemically
different discovery phase research projects. Ranges of IC50 interpolation for each assay were 0.2–50 μM (recombinant CYP) and 0.7–50 μM
(HLM). a Essentially perfect correlation (n=14)—screening assay can be used routinely for optimisation. b Fair correlation with some scatter
and a systematic shift towards higher IC50 values in the human liver microsomal assay (n=22)—screening assay can be used, with testing of
most interesting compounds in HLM assay. c No correlation and gross underestimation of the CYP inhibition potential by the ﬂuorescence-
based assay (n=136)—extensive use of HLM assay required as ﬂuorescence based screening assay not predictive
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Although additional protein may be added to recombinant
enzyme experiments to try to avoid differential protein
binding effects, this is not always done and, even where it is,
the type of protein which is added (e.g. mock transfected
recombinant system protein, human serum albumin) may not
completely prevent differential protein binding effects. Where
calculations of the free IC50 values have been made, these are
often an order of magnitude lower than the measured IC50
values, even where low human liver microsomal concentra-
tions have been used (12). Another reason not to expect
identical behaviour from HLM and recombinantly expressed
enzymes systems is that quite different amounts of CYP
reductase and cytochrome b5 per CYP molecule exist, resulting
in differential catalysis rates and degrees of uncoupling.
Effect of P450 content. The effects of binding to the
target enzyme are seen with extremely potent inhibitors of
relatively abundant CYPs such as ketoconazole (CYP3A4/
CYP3A5) and alpha-naphthoﬂavone (CYP1A2), whose IC50
values change in proportion to enzyme content. Here, the
assumption that total inhibitor concentration and free inhib-
itor concentration are approximately the same is violated, and
at low inhibitor concentrations there may be a titration of
inhibitor with almost stoichiometric binding to enzyme at the
IC50 concentration. With reduction in total human liver
microsomal protein (enzyme) concentration there has there-
fore been a reduction in IC50 values determined for the most
potent CYP inhibitors.
Inhibitor Metabolism. Often discussed, but rarely investi-
gated is the extent of inhibitor metabolism which occurs during
the incubation. If a signiﬁcant proportion of the inhibitor is
metabolised by HLMs compared to a recombinant enzyme
system (or vice versa) and the average inhibition effect is
measured over the total incubation time, there will obviously be
differences in the IC50 values generated. A recent report
showed that considerable inhibitor metabolism may occur
when using 0.5 mg/ml HLM and 20 min incubation time (24).
This was proposed as one of the main reasons for differences in
HLM and recombinant CYP IC50 data. However, in modern
CYP inhibition protocols, where typical HLM concentrations
of 0.05–0.2 mg/ml HLM and incubation times of 3–5 min are
used (9), this should be considerably less problematic.
Where there is signiﬁcant inhibitor turnover, there is also
the possibility that metabolites more inhibitory than the
parent substance are generated in signiﬁcant quantities.
Apart from the instances discussed in the section about
TDI, this is not the norm. There is, after all, a strong element
of lipophilicity associated with CYP inhibition structure–
activity relationships, and when a compound is hydroxylated
the product typically has a lower afﬁnity for the enzyme than
the parent molecule. Where this does not happen, the product
may well undergo a second (or third) metabolic transformation
before release from the enzyme.
Differential Substrate Binding and Hence Differential
Inhibitor Interactions
This phenomenon is best characterised for CYP3A4,
where it has long been known that substrate dependence in
IC50 values occurred. In a systematic study of the effect by
Kenworthy et al (38), the correlation between inhibition data
generated using 10 different CYP3A substrates was analysed,
with some substrates found to behave similarly whilst others
showed quite different patterns of inhibition sensitivity.
Chemically varied CYP3A substrates representative of the
diversity in prescribed drug substances should therefore be
used to ensure adequate assessment of CYP3A4 inhibition
potential. Typically three compounds, such as midazolam,
nifedipine and testosterone are used. The differential inhibi-
tion effects of an example drug candidate molecule are shown
in Fig. 8a. However, it is worth remembering that signiﬁcantly
different inhibition effects are “known outliers” in an
otherwise reasonable correspondence of IC50 values obtained
when similar assay protocols and different substrates are used
(Fig. 8b).
One rationale of the differential inhibition effects which
has gained popular acceptance is that CYP3A4 possesses 3
different binding sites. Perhaps more correctly, once could say
Fig. 8. Differential IC50 Value Determinations using Different
CYP3A4/5 Substrates. a Example of substrate-selective CYP3A4/5
inhibition: no inhibition effect seen using either midazolam (triangles)
or testosterone (circles), but clear inhibition of nifedipine oxidase
activity (squares). b Correlation of IC50 data for 31 (testosterone,
filled circles) or 35 (nifedipine, open squares) structurally diverse test
inhibitors with midazolam IC50 values indicates a generally good
agreement between the assays. Incubations were performed using
0.2 mg/ml pooled HLMs, 1 mM NADPH, incubation time of 5 min
and substrate concentrations of 5 μM midazolam, 10 μM nifedipine or
30 μM testosterone
420 Fowler and Zhangthat the active site is sufﬁciently large as to allow binding of
substrate molecules to different regions, all of which may be
able to access the active site, but with differential binding
characteristics. This hypothesis is consistent with the allosteric
and heterotrophic enhancement effects often seen in CYP3A4
enzyme kinetics (18). Indeed, there is kinetic evidence that
CYP3A4 can bind three molecules simultaneously. In addi-
tion, crystallography studies have shown that the enzyme
possesses an extended active site generally devoid of speciﬁc
ligand-binding residues which allows a complex mode of
interaction with substrate, activator and inhibitor molecules
to exist (39).
USE OF CYP INHIBITION DATA: RANKING,
EXTRAPOLATION AND DDI PREDICTION
In the earliest phases of hit identiﬁcation and lead
optimisation, IC50 and single concentration kobs data can be
used to rank compounds, identify problematic chemistries for
further optimisation and develop structure–activity relation-
ships. (Many structure–activity relationships (40,41)a n d
discussions of substrate binding interactions (42) have been
published for different CYPs; these will not be discussed
further in this review.) Little or no DDI prediction is needed
in the earliest lead optimisation phases, as absolute values
(IC50>1 μM, kobs (10 μM)<0.005 min
−1 for CYPs 1A2, 2C9,
2C19, 2D6 and 3A4) make reasonable optimisation targets.
As compounds progress towards candidate selection, an
assessment of the different DDI risks which compounds
pose must take into account the expected therapeutic
concentrations. A good example of this approach where
both reversible and time dependent inhibition data are
brought together has recently been given by Obach et al.( 33).
For a prediction of the expected clinical DDI effect,
increasingly sophisticated approaches have been applied.
Changes in the area under the plasma concentration–time
curve (AUC) of an oral drug are generally described by the
following equation (43) (Eq. 1):
AUCPO I ðÞ

AUCPO C ðÞ
¼ fa0=fa ðÞ : fg0=fg ðÞ : fh0=fh ðÞ : CLtot=CLtot0 ðÞ ð 1Þ
where AUCpo(c), AUCpo(I),f a,f a′,f g,f g′,f h,f h′,C L tot, and
CLtot′ are the area under the plasma concentration–time
curve, fraction of dose absorbed, fraction of the dose escaping
gut metabolism, fraction of t h ed o s ee s c a p i n gh e p a t i c
metabolism, and total hepatic clearance in the absence and
presence of a CYP inhibitor, respectively. Equation 1 can be
simpliﬁed if liver is the only organ responsible for the
metabolic clearance, the CYP inhibitor does not interfere
with drug absorption and no or minimal gut metabolism and
renal clearance are involved. Therefore, the following equation
(Eq. 2) can be applied when a well-stirred model is considered
(S << KM):
AUCPO I ðÞ

AUCPO C ðÞ
¼ 1

fm:fmCYP

CLint C ðÞ

CLint I ðÞ
 
þ 1   fm:fmCYPg f 

ð2Þ
where fm,f m,CYP,C L int(I) and CLint(C) represent fraction of the
dose metabolized, fraction of the dose metabolized by CYP,
intrinsic clearance in the presence of an inhibitor, and intrinsic
clearance in the absence of an inhibitor, respectively. Simu-
lations based on Eq. 2 indicate clearly that the change in AUC
(AUCpo(I)/AUCpo(C) ratio) is sensitive to the product of fm and
fm,CYP (i.e., fm   fm;CYP )( 44–46). Although not obvious, it is
worth noting that changes in AUC are also sensitive to the
CLint in the absence of the inhibitor.
Mode of inhibition—reversible inhibition. Depending on
the kinetic behaviour of enzyme, substrate and inhibitor,
reversible CYP inhibition can be described as competitive,
non-competitive, un-competitive and mixed (47). Cases of
competitive inhibition are most frequently assessed. Here, the
AUCPO(I)/AUCPO(C) ratio can be expressed as (Eq. 3):
AUCPO I ðÞ

AUCPO C ðÞ
¼ 1= fm:fmCYP= 1 þ I ½  =KI ðÞ ½  fg þ 1   fm:fmCYPg f   ½ð 3Þ
Where [I] and Ki are the inhibitor concentration at the site of
inhibition and the inhibition constant, respectively. The inhib-
itor concentration, [I], is often based on plasma concentrations
because concentrations at the site of inhibition cannot be
measured (47,44). Because of this, various inhibitor concen-
trations including plasma Cmax, plasma free Cmax, portal vein
Cmax (inlet liver concentration) and portal vein free Cmax have
been explored for prediction accuracy (44,47–49). In some
cases, the use of portal vein Cmax is fairly accurate in DDI
prediction and for other compounds the portal vein free Cmax
or plasma Cmax is reasonable as well. In addition, physiolog-
ically based pharmacokinetic models have been examined,
which take into consideration dynamic (as opposed to static)
inhibitor concentrations (50). Furthermore, absorption rate
constants of CYP inhibitors may be incorporated into the
prediction model, leading to a reduction in overprediction for
some CYP2D6 and CYP3A4 substrates (44,51).
Mode of inhibition—mechanism-based inactivation.
Mechanism-based CYP inhibition or irreversible inhibition,
involves permanent inactivation of CYP enzymes. Prediction
of in vivo drug interactions for mechanism-based inhibitors is
more complex and modiﬁed equations are therefore required
to take into account the balance between enzyme inactivation
and new enzyme synthesis. For mechanism-based inactivation,
the AUCPO(I)/AUCPO(C) ratio is described as (Eq. 4)( 52):
AUCPO I ðÞ

AUCPO C ðÞ
¼ 1

fm:fmCYP

1 þ kinact

kdeg

* I ½  =KI ðÞ
 
þ 1   fm:fmCYPg f  

ð4Þ
Where kinact,K I and kdeg represent the maximal rate of enzyme
inactivation at saturation, concentration of inhibitor that
produces half maximal inactivation, and turnover rate of the
inhibited enzyme, respectively. Values of kinact and KI can be
determined experimentally (35)a n dkdeg for each CYP
enzymes is often assigned based on values reported in the
literature. Galetin et al (45) examined a wide range of kdeg
values (0.0005 to 0.00008 min
−1) for CYP3A4 and found that a
kdeg of 0.00016 min
−1 y i e l d e da n8 9 %s u c c e s sr a t e( d e ﬁned by
<2-fold of observed in vivo values) of predicting mechanism-
based inactivation. However, uncertainties in experimental
design and data generation (kinact,K I and kdeg), inhibitor
421 In Vitro CYP Inhibition Measurement: Current Status and DDI Predictionconcentration used (for example, plasma Cmax vs.p o r t a lv e i n
Cmax), and quality of clinical drug interaction data may
contribute to discrepancies in the prediction (33).
Parallel pathways. The value of fm,CYP is the most
important parameter for the prediction of in vivo drug
interactions. It is well recognized that a substrate cleared
primarily by a single CYP enzyme (fm,CYP>0.8) has a far
greater potential for DDIs than those eliminated via multiple
metabolic or excretory pathways. Ito et al (53) recently
examined the impact of parallel pathways for the prediction
of in vivo interactions for CYP2D6 substrates and found that
the number of over-predictions was signiﬁcantly reduced by
incorporating an additional pathway. The model was also
useful in investigation the role of CYP2D6 polymorphism in
the prediction of DDIs and has been extended for other
CYPs (45,51). It is clear that the accuracy of prediction can be
improved with the consideration of additional clearance
pathways and these studies highlight the importance of
multiple clearance routes in reducing the liability of a drug
substance to be a victim of DDIs.
OPINION AND FUTURE PERSPECTIVES
TDI Profiling
Several important advances have been made in the
implementation and design of TDI testing over recent years.
These include: (1) the almost universal adoption of some sort
of TDI testing programme within pharmaceutical companies
and contract research organisations performing CYP inhibi-
tion studies, (2) the identiﬁcation of a number of compounds
which can be used as positive control substances for
individual CYP TDI assays and (3) improvements in assay
design (made possible by improved analytical sensitivity) to
generate more accurate KI and kinact parameter estimates for
use in in vitro–in vivo extrapolations. However, current TDI
effect prediction methods are restricted by differences in TDI
effects observed using different experimental systems (54),
the complex interplay between inactivation and induction and
uncertainty as to the actual rate of enzyme re-synthesis in
man. Clinical studies are therefore still required to establish
the true effect of a TDI positive substance in vivo.
CYP IC50 Screening
Most large pharmaceutical companies currently apply a
combination of high and low throughput CYP inhibition
screening methodologies to address the different needs of
discovery and development projects. However, as the time
costs of performing the necessary correlation work can be
high (and the costs of misguided compound optimisation even
higher), and with the decreasing costs associated with
miniaturised assay formats, lower HLM concentrations and
possibility to perform pooled sample analysis by LC-MS/MS,
there is increasing use of human liver microsomal assays as
the primary screening system. This allows a consistency of
approach to be implemented and prevents chemical optimi-
sation based upon data which may be different to that used in
the ﬁnal DDI risk assessment process.
Future perspectives for truly high-throughput MS/MS
analysis remove the need for a chromatography step, the
most time consuming part of the analysis process. Thermal or
matrix-assisted laser desorption ionization (55) and direct
sample injection technologies are examples of methods
currently being developed.
Investigation of DDI In Vivo Using Animal Models
The science of in vivo DDI investigations using preclin-
ical animal species has shown progress in recent years, with
more studies being published describing drug treatment
regimens and a growing number of recombinantly expressed
non-human CYPs available for reaction phenotyping experi-
ments. Although extrapolation of animal DDI study data to
the human situation is fraught with complications (e.g. species
differences in: substrate metabolism rates and routes, inhib-
itor selectivity, pharmacokinetics and tissue concentrations)
use of animal data could help to de-risk the development of
compounds where the in vitro human CYP data indicates a
high risk of DDI, but where other factors may attenuate the
impact of enzyme inhibition in vivo (56). Work has mainly
been concentrated around CYP3A mediated metabolism in
various species, making use of probe substrates and inhibitors
such as midazolam and ketoconazole (56–58). However,
although these substances are known to be highly CYP3A
selective in man, the contribution of non-CYP3A enzymes to
midazolam metabolism in the rat and the inhibition of
multiple rat CYPs by ketoconazole encountered in a recent
study by Mandlekar et al (59) exempliﬁed the current
difﬁculty in performing animal DDI studies from which clear
conclusions for the human situation can be drawn. Future
developments in this area are likely to come from a more
detailed understanding of the enzymology of individual animal
CYPs and progress in the development of “humanized”
animals whose endogenous drug-metabolising enzymes have
been genetically replaced with their human counterparts.
Human In Vivo DDI Prediction
Prospectively, there are always instances where in vivo
human outcomes could not be fully appreciated from in vitro
data. Retrospectively, however, in vitro systems are valuable
tools to understand clinical DDIs. Cerivastatin, a potent
HMGCoA reductase inhibitor, was thought to be at low risk
of metabolism inhibition because the compound was metab-
olized by both CYP3A4 and CYP2C8; and the lack of
clinically relevant interactions with commonly used drugs
appeared to support this hypothesis (60). However, a
signiﬁcant interaction with gemﬁbrozil, and concerns over
severe rhabdomyolysis associated with this type of interac-
tion, led to its eventual withdrawl from the market (61,62).
Subsequent investigative studies indicated that gemﬁbrozil-O-
glucuronide, a major metabolite of gemﬁbrozil, is an inhibitor
of cerivastatin hepatic uptake transport via the organic anion
transporter protein, as well as a mechanism-based inactivator
of CYP2C8 (63,64). Therefore, the impact of gemﬁbrozil on
cerivastatin pharmacokinetics is likely to have been caused by
a combination of hepatic uptake and CYP2C8 inhibition. This
example clearly demonstrates the need to thoroughly exam-
422 Fowler and Zhangine the roles of CYP-mediated metabolism in the context of
other metabolic and transport processes involved in drug
disposition.
Nevertheless, predictions of the likely interaction effect
with competitive inhibitors based upon the in vitro CYP
kinetics and fm calculations are reasonably well accepted. The
current challenge is to simulate the time- and concentration-
dependent effects of irreversible inactivators, quasi-irreversible
inhibitors and inducer compounds on the pharmacokinetics of
well established probe substrates. Various approaches can be
taken to modelling DDIs, either using equations to predict the
overall DDI magnitude or by modelling the inhibition effect
with time over the period where exposure to both compounds
is expected. Tools which have been applied range from home-
made spreadsheets (65) to use of commercial pharmacokinetics
and DDI modelling programs. Of these, the SimCYP software
package provides the most sophisticated approach to simula-
tion of clinical DDI studies, allowing substrate and inhibitor
concentrations to be modelled over the time of a simulated
clinical study in a population of virtual individuals, each with
their own enzymatic and physiological status parameters, to
give a population-based estimate of the DDI risk (66,67). The
inclusion of TDI and induction effects into the simulations
offers the possibility to come even closer to the in vivo
situation.
As with all modelling and simulation, the value of the
predictions is directly dependent upon the quality and correct
manipulation of the input data. High quality experimental
practices and scientiﬁcally rigorous assessment will therefore
remain a cornerstone of DDI avoidance and risk assessment.
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